Literature DB >> 21878461

Disproportionality methods for pharmacovigilance in longitudinal observational databases.

Ivan Zorych1, David Madigan, Patrick Ryan, Andrew Bate.   

Abstract

Data mining disproportionality methods (PRR, ROR, EBGM, IC, etc.) are commonly used to identify drug safety signals in spontaneous report system (SRS) databases. Newer data sources such as longitudinal observational databases (LOD) provide time-stamped patient-level information and overcome some of the SRS limitations such as an absence of the denominator, total number of patients who consume a drug, and limited temporal information. Application of the disproportionality methods to LODs has not been widely explored. The scale of the LOD data provides an interesting computational challenge. Larger health claims databases contain information on more than 50 million patients and each patient has records for up to 10 years. In this article we systematically explore the application of commonly used disproportionality methods to simulated and real LOD data.

Entities:  

Mesh:

Year:  2011        PMID: 21878461     DOI: 10.1177/0962280211403602

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  35 in total

1.  Identifying Adverse Drug Events by Relational Learning.

Authors:  David Page; Vítor Santos Costa; Sriraam Natarajan; Aubrey Barnard; Peggy Peissig; Michael Caldwell
Journal:  Proc Conf AAAI Artif Intell       Date:  2012-07

2.  Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.

Authors:  Vaishali K Patadia; Martijn J Schuemie; Preciosa Coloma; Ron Herings; Johan van der Lei; Sabine Straus; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Int J Clin Pharm       Date:  2014-12-09

Review 3.  Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?

Authors:  Christiane Michel; Emil Scosyrev; Michael Petrin; Robert Schmouder
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

4.  Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions.

Authors:  Rave Harpaz; Santiago Vilar; William Dumouchel; Hojjat Salmasian; Krystl Haerian; Nigam H Shah; Herbert S Chase; Carol Friedman
Journal:  J Am Med Inform Assoc       Date:  2012-10-31       Impact factor: 4.497

5.  Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records.

Authors:  Mei Liu; Eugenia Renne McPeek Hinz; Michael Edwin Matheny; Joshua C Denny; Jonathan Scott Schildcrout; Randolph A Miller; Hua Xu
Journal:  J Am Med Inform Assoc       Date:  2012-11-17       Impact factor: 4.497

Review 6.  Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

7.  Detection of pharmacovigilance-related adverse events using electronic health records and automated methods.

Authors:  K Haerian; D Varn; S Vaidya; L Ena; H S Chase; C Friedman
Journal:  Clin Pharmacol Ther       Date:  2012-06-20       Impact factor: 6.875

Review 8.  Novel data-mining methodologies for adverse drug event discovery and analysis.

Authors:  R Harpaz; W DuMouchel; N H Shah; D Madigan; P Ryan; C Friedman
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

9.  An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.

Authors:  Xiaofeng Zhou; Sundaresan Murugesan; Harshvinder Bhullar; Qing Liu; Bing Cai; Chuck Wentworth; Andrew Bate
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

10.  Signalling paediatric side effects using an ensemble of simple study designs.

Authors:  Jenna M Reps; Jonathan M Garibaldi; Uwe Aickelin; Daniele Soria; Jack E Gibson; Richard B Hubbard
Journal:  Drug Saf       Date:  2014-03       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.